Skip to main content

Advertisement

SpringerLink
Log in

Double-Blind Comparison of Lansoprazole 15 mg, Lansoprazole 30 mg, and Placebo in the Maintenance of Healed Gastric Ulcer

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Our purpose was to compare the safety andefficacy of lansoprazole 15 mg and 30 mg with placebo inpreventing recurrence in 49 patients with a history ofgastric ulcer. Within one month, 40% of patients receiving placebo experienced ulcer recurrencecompared to 0% and 7% of patients receiving lansoprazole15 mg and 30 mg, respectively. All placebo patientsbecame symptomatic, experienced ulcer recurrence or withdrew from the study by month 9. Ascompared to placebo, a significantly (P < 0.001)higher percentage of patients treated with lansoprazole15 mg (83%) and lansoprazole 30 mg (93%) with healed gastric ulcer disease remained healed at month12. Of patients asymptomatic at baseline, 100% and 59%of those treated with lansoprazole 15 mg and 30 mg,respectively, remained asymptomatic at month 12. The incidence of adverse events was comparableamong the treatment groups. Lansoprazole safely andeffectively reduces ulcer recurrence in patients with ahistory of gastric ulcer disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Ihamaki T, Varis K, Siurela M: Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol 14:801 - 812, 1979

    Google Scholar 

  2. Kurata JH, Haile BM: Epidemiology of peptic ulcer disease. Clin Gastroenterol 13:289 - 305, 1984

    Google Scholar 

  3. Kurata JH, Nogowa AN, Abbey DE, Petersen F: A prospective study of risk for peptic ulcer disease in Seventh-Day Adventist. Gastroenterology 102:902 - 909, 1992

    Google Scholar 

  4. Bonnevie O: The incidence of duodenal ulcer in Copenhagen County. Scand J Gastroenterol 10:385 - 393, 1975

    Google Scholar 

  5. Bonnevie O: The incidence of gastric ulcer in Copenhagen County. Scand J Gastroenterol 10:231 - 239, 1975

    Google Scholar 

  6. School I-M, Mellstrom D, Oden A, Ytterberg B-O: Incidence of peptic ulcer disease in Gothenburg 1985. Br Med J 299:1131 - 1134, 1989

    Google Scholar 

  7. Jaszewski R, Calzada R, Dhar R: Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin. Dig Dis Sci 34:1361 - 1364, 1989

    Google Scholar 

  8. Collins AJ, Davies J, Dixon AS: A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol 27:106 - 109, 1988

    Google Scholar 

  9. Tytgat GNJ, Rauws EAJ: Campylobacter pyloriand its role in peptic ulcer disease. Gastroenterol Clin North Am 19:183 - 196, 1990

    Google Scholar 

  10. Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, Baskin WN, MacKercher PA, Hewett J: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91:517 - 520, 1979

    Google Scholar 

  11. Penston JG, Wormsley KG: Review article: Maintenance treatment with H2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 6:3 - 29, 1992

    Google Scholar 

  12. Soll AH: Gastric, duodenal, and stress ulcer. InGastrointestinal Disease: Pathophysiology/Diagnosis/Management. M Sleisenger, J Fordtran (eds). Philadelphia, Saunders, 1993, pp 580 - 679

  13. Taha AS, Hudson N, Hawkey CJ, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435 - 1439, 1996

    Google Scholar 

  14. Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T: A controlled study of ranitidine for the prevention of recurre nt hemorrhage from duodenal ulcer. N Engl J Med 330:382 - 386, 1994

    Google Scholar 

  15. Holt S, Howden CW: Omeprazole: Overview and opinion. Dig Dis Sci 36:385 - 393, 1991

    Google Scholar 

  16. Nagaya H, Satoh H, Maki Y: Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289 - 1295, 1989

    Google Scholar 

  17. Sachs G, Shin JM, Besancon M, Prinz C: The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 7(suppl 1):4 - 12, 29 - 31, 1993

    Google Scholar 

  18. Tolman KG, Sanders SW, Buchi KN: Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 106(suppl 4):A172, 1994

    Google Scholar 

  19. Müller P, Dammann HG, Leucht U, Simon B: Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 3:193 - 198, 1989

    Google Scholar 

  20. Takemoto T, Namiki M, Goto Y: Clinical evaluation of lansoprazole (AG-1749) for gastric ulcer: A multicenter doubleblind comparison with famotidine. Rinsho Seijinbyo 21:327 - 345, 1991

    Google Scholar 

  21. Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, Sjostedt S, Smith PM, Stig R, Wormsley RG: Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 8:215 - 220, 1994

    Google Scholar 

  22. Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud JC, Dupas JL, Bigard MA, Vervae rd JC: Treatme nt of gastric ulcer with lansoprazole or ranitidine: A multicentre clinical trial. Aliment Pharmacol Ther 8:119 - 122, 1994

    Google Scholar 

  23. Florent C, Forestier M, Joubert-Collin M: Lansoprazole versus omeprazole: Efficacy and safety in acute gastric ulcer. Gastroente-rology 104:A80, 1993

    Google Scholar 

  24. Tielemans Y, Hakanson R, Sundler F, Willems G: Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology 96:723 - 729, 1989

    Google Scholar 

  25. Misawa T, Chijiiwa Y, Imazono Y: Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res 122:175 - 189, 1991

    Google Scholar 

  26. Ogoshi K, Kato T, Saito S: Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin leve ls and gastric mucosal ECL cell density. Yakuri Chiryo 19:933 - 946, 1991

    Google Scholar 

  27. Larsson H, Carlsson E, Hakanson R, Mattsson H, Nilsson G, Seensalu R, Wallmark B, Sundler F: Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology 95:1477 - 1486, 1988

    Google Scholar 

  28. Brunner G, Arnold R, Hennig U, Fuchs W: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 7(suppl 1):51 - 55, 1993

    Google Scholar 

  29. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Grimelius L, Havu N: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41:185 - 200, 1988

    Google Scholar 

  30. Sharma B, Axelson M, Pounder RE, et al: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1:67 - 76, 1987

    Google Scholar 

  31. Karnes WE, Berlin RG, Maxwell V, et al: Prolonged inhibition of acid secretion causes hypergastrinaemia without altering pH inhibition of gastrin release in humans. Aliment Pharmacol Ther 4:443 - 456, 1990

    Google Scholar 

Download references

Authors
  1. Thomas O.G. Kovacs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marian Haber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pamela Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dennis E. Jennings
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joel Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovacs, T.O., Campbell, D., Haber, M. et al. Double-Blind Comparison of Lansoprazole 15 mg, Lansoprazole 30 mg, and Placebo in the Maintenance of Healed Gastric Ulcer. Dig Dis Sci 43, 779–785 (1998). https://doi.org/10.1023/A:1018818115047

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018818115047

Search

Navigation